Metraipolis › archive › dc_dec97a16ea48

Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients — Europe PMC PMID:41476990

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41476990
DOI: 10.3389/fimmu.2025.1727312
License (as archived): solo-consultazione
Archived: 2026-11-07T15:08:38.826Z
SHA-256 of the archived text: 2f5fe6bf2206a3d7769d2d3240a1933cc3e39416453df2c0b22bf85348868844
Stable URL of this page: https://metraipolis.com/documento/dc_dec97a16ea48

How to cite

Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients — Europe PMC PMID:41476990 — Europe PMC (en), https://europepmc.org/article/MED/41476990 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_dec97a16ea48 (Metraipolis archive dc_dec97a16ea48, sha256 2f5fe6bf2206a3d7769d2d3240a1933cc3e39416453df2c0b22bf85348868844)

BibTeX

@misc{dcdec97a16ea48,
  title = {Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients — Europe PMC PMID:41476990},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41476990},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_dec97a16ea48; sha256 2f5fe6bf2206a3d7769d2d3240a1933cc3e39416453df2c0b22bf85348868844},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41476990. Agents can read the archived copy with the MCP tool read_document.